- Medicine Name- Bebtelovimab
- API- Bebtelovimab
- Strength- Injection: 175 mg/2 mL (87.5 mg/mL) in a single dose vial
- Manufactured by- Eli Lilly and Company
Bebtelovimab is authorized for emergency use in the treatment of COVID-19. It is specifically intended for individuals with mild-to-moderate symptoms who are not hospitalized or requiring oxygen therapy or respiratory support. The monoclonal antibody aims to mitigate the severity of the disease caused by SARS-CoV-2.
Recommended Dosage: For adults (18 years and older) and pediatric patients (≥12 years, weighing at least 40 kg), the recommended dosage is 175 mg administered as a single intravenous injection over at least 30 seconds. Bebtelovimab should be administered as soon as possible after positive SARS-CoV-2 viral testing and within 7 days of symptom onset.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.